Finch Therapeutics Group Stock Profit Margin
Finch Therapeutics Group fundamentals help investors to digest information that contributes to Finch Therapeutics' financial success or failures. It also enables traders to predict the movement of Finch Pink Sheet. The fundamental analysis module provides a way to measure Finch Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Finch Therapeutics pink sheet.
Finch |
Finch Therapeutics Group Company Profit Margin Analysis
Finch Therapeutics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Finch Therapeutics Group has a Profit Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
Finch Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Finch Therapeutics' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Finch Therapeutics could also be used in its relative valuation, which is a method of valuing Finch Therapeutics by comparing valuation metrics of similar companies.Finch Therapeutics is currently under evaluation in profit margin category among its peers.
Finch Fundamentals
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 10.74 M | ||||
| Shares Outstanding | 1.61 M | ||||
| Shares Owned By Insiders | 53.48 % | ||||
| Shares Owned By Institutions | 11.35 % | ||||
| Number Of Shares Shorted | 19.2 K | ||||
| Price To Book | 0.14 X | ||||
| Price To Sales | 30.46 X | ||||
| Revenue | 107 K | ||||
| Gross Profit | (57.03 M) | ||||
| EBITDA | (32.48 M) | ||||
| Net Income | (74.75 M) | ||||
| Cash And Equivalents | 104.67 M | ||||
| Cash Per Share | 2.19 X | ||||
| Total Debt | 30.13 M | ||||
| Debt To Equity | 0.35 % | ||||
| Current Ratio | 7.28 X | ||||
| Book Value Per Share | 11.86 X | ||||
| Cash Flow From Operations | (31.5 M) | ||||
| Short Ratio | 0.19 X | ||||
| Earnings Per Share | (6.59) X | ||||
| Price To Earnings To Growth | (0.02) X | ||||
| Target Price | 90.0 | ||||
| Beta | 0.46 | ||||
| Market Capitalization | 1.94 M | ||||
| Total Asset | 71 M | ||||
| Retained Earnings | (350.39 M) | ||||
| Working Capital | 21.76 M | ||||
| Net Asset | 71 M |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |